Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2012, Pages 85-105

  Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ABC transporters; ABCB1); ABCG2); Breast cancer resistance protein (BCRP; P glycoprotein (MDR1; Pharmacogenomics

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATAZANAVIR; ATORVASTATIN; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; CLOPIDOGREL; COLCHICINE; CYCLOSPORIN; DOCETAXEL; DOMPERIDONE; DOXORUBICIN; EFAVIRENZ; FLUOROURACIL; FOLIC ACID; GLYCOPROTEIN P; GUANFACINE; IMATINIB; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; OXYCODONE; PACLITAXEL; PAROXETINE; RISPERIDONE; TICAGRELOR; UNINDEXED DRUG; VALPROIC ACID; XENOBIOTIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; AUTISM; BCRP GENE; BEHCET DISEASE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CONGENITAL HEART DISEASE; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EPILEPSY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HAND FOOT SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; HYPERBILIRUBINEMIA; INTESTINE ABSORPTION; LIVER TOXICITY; LUNG CANCER; MARKER GENE; MDR1 GENE; MYALGIA; MYELOMA; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PHARMACOGENOMICS; PHARMACOKINETICS; POSTOPERATIVE PAIN; PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH PARESIS;

EID: 84857768340     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RV-098     Document Type: Review

References (250)

1. Ieiri, I., Takane, H. and Otsubo, K.: The MDR1 ABCB1 gene polymorphism and its clinical implications. Clin. Pharmacokinet., 43: 553-576 2004.
2. Ieiri, I., Takane, H., Hirota, T., Otsubo, K. and Higuchi, S.: Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin. Drug Metab. Toxicol., 2: 651-674 2006.
3. Ieiri, I., Higuchi, S. and Sugiyama, Y.: Genetic polymorphisms of uptake OATP1B1, 1B3 and efflux MRP2, BCRP transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol., 5: 703-729 2009.
4. Cordon-Cardo, C., OöBrien, J. P., Boccia, J., Casals, D., Bertino, J. R. and Melamed, M. R.: Expression of the multidrug resistance gene product P-glycoprotein in human normal and tumor tissues. J. Histochem. Cytochem., 38: 1277-1287 1990.
5. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738 1987.
6. Borst, P., Schinkel, A. H., Smit, J. J., Wagenaar, E., Van Deemter, L., Smith, A. J., Eijdems, E. W., Baas, F. and Zaman, G. J.: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmacol. Ther., 60: 289-299 1993.
7. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M. and Pastan, I.: Expression of a multidrugresistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84: 265-269 1987.
8. Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. and Mori, S.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistance gene as revealed by a monoclonal antibody, MRK16. Cancer Res., 48: 1926-1929 1988.
9. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M. and Wilkinson, G. R.: The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101: 289-294 1998.
10. Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K., van Asperen, J., Borst, P. and Schinkel, A. H.: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by mdr1a Pglycoprotein. Br. J. Pharmacol., 119: 1038-1044 1996.
11. Nakamura, Y., Ikeda, S., Furukawa, T., Sumizawa, T., Tani, A., Akiyama, S. and Nagata, Y.: Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun., 235: 849-853 1997.
12. Schinkel, A. H., Wagenaar, E., Mol, C. A. and van Deemter, L.: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97: 2517-2524 1996.
13. Cordon-Cardo, C., OöBrien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R.: Multidrugresistance gene P-glycoprotein is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 86: 695-698 1989.
14. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M., Fibbe, W. E. and Borst, P.: Normal viability and altered pharmacokinetics in mice lacking mdr1-type drug-transporting P-glycoprotein. Proc. Natl. Acad. Sci. USA, 94: 4028-4033 1997.
15. Wacher, V. J., Wu, C. Y. and Benet, L. Z.: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13: 129-134 1995.
16. Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., Wood, A. J. and Wilkinson, G. R.: Interrelationship between substrates and inhibitors of human CYP3A and Pglycoprotein. Pharm. Res., 16: 408-414 1999.
17. Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A. and Pastan, I.: Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 29: 607-649 1995.
18. Mickley, L. A., Lee, J. S., Weng, Z., Zhan, Z., Alvarez, M., Wilson, W., Bates, S. E. and Fojo, T.: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood, 91: 1749-1756 1998.
19. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 97: 3473-3478 2000.
20. Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., Kigawa, J., Higuchi, S., Terakawa, N. and Otsubo, K.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance MDR-1 gene. J. Pharmacol. Exp. Ther., 297: 1137-1143 2001.
21. Ito, S., Ieiri, I., Tanabe, M., Suzuki, A., Higuchi, S. and Otsubo, K.: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics, 11: 175-184 2001.
22. Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U. and Roots, I.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther., 69: 169-174 2001.
23. Kim, R. B., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H. G., McKinsey, J., Zhou, S., Lan, L. B., Schuetz, J. D., Schuetz, E. G. and Wilkinson, G. R.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther., 70: 189-199 2001.
24. Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K. and Cascorbi, I.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther., 72: 572-583 2002.
25. Schwab, M., Eichelbaum, M. and Fromm, M. F.: Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol., 43: 285-307 2003.
26. Sakaeda, T.: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet., 20: 391-414 2005.
27. Pauli-Magnus, C. and Kroetz, D. L.: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 ABCB1. Pharm. Res., 21: 904-913 2004.
28. Marzolini, C., Paus, E., Buclin, T. and Kim, R. B.: Polymorphisms in human MDR1 P-glycoprotein: recent advances and clinical relevance. Clin. Pharmacol. Ther., 75: 13-33 2004.
29. Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., Kasuga, M. and Okumura, K.: MDR1 genotyperelated pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res., 18: 1400-1404 2001.
30. Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S., Urae, A., Ohdo, S., Ohtani, H., Sawada, Y., Higuchi, S. and Otsubo, K.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther., 72: 209-219 2002.
31. Jiang, Z. P., Wang, Y. R., Xu, P., Liu, R. R., Zhao, X. L. and Chen, F. P.: Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin. Pharmacol. Toxicol., 103: 433-444 2008.
32. Gex-Fabry, M., Eap, C. B., Oneda, B., Gervasoni, N., Aubry, J. M., Bondolfi, G. and Bertschy, G.: CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit., 30: 474-482 2008.
33. Nikisch, G., Eap, C. B. and Baumann, P.: Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Psychopharmacology Berl., 181: 751-760 2005.
34. Fukui, N., Suzuki, Y., Sawamura, K., Sugai, T., Watanabe, J., Inoue, Y. and Someya, T.: Dose-dependent effects of the 3435ChT genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther. Drug Monit., 29: 185-189 2007.
35. Elger, C. E. and Schmidt, D.: Modern management of epilepsy: a practical approach. Epilepsy Behav., 12: 501-539 2008.
36. Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W. and Sisodiya, S. M.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med., 348: 1442-1448 2003.
37. Haerian, B. S., Roslan, H., Raymond, A. A., Tan, C. T., Lim, K. S., Zulkifli, S. Z., Mohamed, E. H., Tan, H. J. and Mohamed, Z.: ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and metaanalysis. Seizure, 19: 339-346 2010.
38. Bournissen, F. G., Moretti, M. E., Juurlink, D. N., Koren, G., Walker, M. and Finkelstein, Y.: Polymorphism of the MDR1/ ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia, 50: 898-903 2009.
39. Leschziner, G. D., Andrew, T., Leach, J. P., Chadwick, D., Coffey, A. J., Balding, D. J., Bentley, D. R., Pirmohamed, M. and Johnson, M. R.: Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet. Genomics, 17: 217-220 2007.
40. Marsh, S., Paul, J., King, C. R., Gifford, G., McLeod, H. L. and Brown, R.: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol., 25: 4528-4535 2007.
41. Johnatty, S. E., Beesley, J., Paul, J., Fereday, S., Spurdle, A. B., Webb, P. M., Byth, K., Marsh, S. and McLeod, H.: AOCS Study Group: Harnett, P. R., Brown, R., DeFazio, A. and Chenevix- Trench, G.: ABCB1 MDR 1 polymorphisms and progressionfree survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res., 14: 5594-5601 2008.
42. Taub, M. E., Mease, K. M., Sane, R. S., Watson, C. A., Chen, L., Ellens, H., Hirakawa, B. P., Reyner, E. L., Jani, M. and Lee, C. A.: Digoxin is not a Substrate for Organic Anion Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a Substrate for a Sodium Dependent Transporter Expressed in HEK293 Cells. Drug Metab. Dispos., 39: 2093-2102 2011.
43. Ming, X., Knight, B. M. and Thakker, D. R.: Vectorial Transport of Fexofenadine across Caco-2 Cells: Involvement of Apical Uptake and Basolateral Efflux Transporters. Mol. Pharm., 8: 1677-1686 2011.
44. Takano, A., Kusuhara, H., Suhara, T., Ieiri, I., Morimoto, T., Lee, Y. J., Maeda, J., Ikoma, Y., Ito, H., Suzuki, K. and Sugiyama, Y.: Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med., 47: 1427-1433 2006.
45. Brunner, M., Langer, O., Sunder-Plassmann, R., Dobrozemsky, G., Müller, U., Wadsak, W., Krcal, A., Karch, R., Mannhalter, C., Dudczak, R., Kletter, K., Steiner, I., Baumgartner, C. and Müller, M.: Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther., 78: 182-190 2005.
46. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. and Ross, D. D.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670 1998.
47. Staud, F. and Pavek, P.: Breast cancer resistance protein BCRP/ ABCG2. Int. J. Biochem. Cell Biol., 37: 720-725 2005.
48. Xu, J., Liu, Y., Yang, Y., Bates, S. and Zhang, J. T.: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol. Chem., 279: 19781-19789 2004.
49. Kage, K., Tsukahara, S., Sugiyama, T., Asada, S., Ishikawa, E., Tsuruo, T. and Sugimoto, Y.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer, 97: 626-630 2002.
50. Iida, A., Saito, S., Sekine, A., Mishima, C., Kitamura, Y., Kondo, K., Harigae, S., Osawa, S. and Nakamura, Y.: Catalog of 605 single-nucleotide polymorphisms SNPs among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet., 47: 285-310 2002.
51. Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K., Schuetz, J. D. and Schuetz, E. G.: Natural allelic variants of breast cancer resistance protein BCRP and their relationship to BCRP expression in human intestine. Pharmacogenetics, 13: 19-28 2003.
52. Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., Otsubo, K., Mine, K. and Sugiyama, Y.: Functional assessment of ABCG2 BCRP gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos., 33: 94-101 2005.
53. Bäckström, G., Taipalensuu, J., Melhus, H., Brändström, H., Svensson, A. C., Artursson, P. and Kindmark, A.: Genetic variation in the ATP-binding cassette transporter gene ABCG2 BCRP in a Swedish population. Eur. J. Pharm. Sci., 18: 359-364 2003.
54. Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., Twelves, C., Verweij, J. and McLeod, H. L.: Diflomotecan pharmacokinetics in relation to ABCG2 421ChA genotype. Clin. Pharmacol. Ther., 76: 38-44 2004.
55. Kondo, C., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J., Kobayashi, D., Ieiri, I., Mine, K., Ohtsubo, K. and Sugiyama, Y.: Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res., 21: 1895-1903 2004.
56. Nakagawa, H., Tamura, A., Wakabayashi, K., Hoshijima, K., Komada, M., Yoshida, T., Kometani, S., Matsubara, T., Mikuriya, K. and Ishikawa, T.: Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem. J., 411: 623-631 2008.
57. Furukawa, T., Wakabayashi, K., Tamura, A., Nakagawa, H., Morishima, Y., Osawa, Y. and Ishikawa, T.: Major SNP Q141K variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm. Res., 26: 469-479 2009.
58. Sparreboom, A., Loos, W. J., Burger, H., Sissung, T. M., Verweij, J., Figg, W. D., Nooter, K. and Gelderblom, H.: Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther., 4: 650-653 2005.
59. Zhang, W., Yu, B. N., He, Y. J., Fan, L., Li, Q., Liu, Z. Q., Wang, A., Liu, Y. L., Tan, Z. R., Fen-Jiang, Huang, Y. F. and Zhou, H. H.: Role of BCRP 421ChA polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta, 373: 99-103 2006.
60. Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., Higuchi, S. and Sugiyama, Y.: Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 BCRP gene polymorphisms in humans. Clin. Pharmacol. Ther., 84: 95-103 2008.
61. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L. and Ware, J. A.: Breast cancer resistance protein Bcrp/abcg2 is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm., 3: 55-61 2006.
62. Han, J. Y., Lim, H. S., Yoo, Y. K., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J. E., Lee, D. H., Kim, H. T. and Lee, J. S.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 110: 138-147 2007.
63. de Jong, F. A., Marsh, S., Mathijssen, R. H., King, C., Verweij, J., Sparreboom, A. and McLeod, H. L.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res., 10: 5889-5894 2004.
64. Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., Higuchi, S. and Sugiyama, Y.: SLCO1B1 OATP1B1, an uptake transporter and ABCG2 BCRP, an efflux transporter variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 82: 541-547 2007.
65. Zamboni, W. C., Ramanathan, R. K., McLeod, H. L., Mani, S., Potter, D. M., Strychor, S., Maruca, L. J., King, C. R., Jung, L. L., Parise, R. A., Egorin, M. J., Davis, T. A. and Marsh, S.: Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest. New Drugs, 24: 393-401 2006.
66. Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R. G., Verweij, J., Ludovini, V., Villa, E. and Hidalgo, M.: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst., 98: 1739-1742 2006.
67. Akasaka, K., Kaburagi, T., Yasuda, S., Ohmori, K., Abe, K., Sagara, H., Ueda, Y., Nagao, K., Imura, J. and Imai, Y.: Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother. Pharmacol., 66: 691-698 2010.
68. Lemos, C., Giovannetti, E., Zucali, P. A., Assaraf, Y. G., Scheffer, G. L., van der Straaten, T., DöIncecco, A., Falcone, A., Guchelaar, H. J., Danesi, R., Santoro, A., Giaccone, G., Tibaldi, C. and Peters, G. J.: Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics, 12: 159-170 2011.
69. Thomas, F., Rochaix, P., White-Koning, M., Hennebelle, I., Sarini, J., Benlyazid, A., Malard, L., Lefebvre, J. L., Chatelut, E. and Delord, J. P.: Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur. J. Cancer, 45: 2316-2323 2009.
70. Mizuno, T., Terada, T., Kamba, T., Fukudo, M., Katsura, T., Nakamura, E., Ogawa, O. and Inui, K.: ABCG2 421ChA polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann. Oncol., 21: 1382-1383 2010.
71. Takenaka, K., Morgan, J. A., Scheffer, G. L., Adachi, M., Stewart, C. F., Sun, D., Leggas, M., Ejendal, K. F., Hrycyna, C. A. and Schuetz, J. D.: Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res., 67: 6965-6972 2007.
72. Yang, Q., Köttgen, A., Dehghan, A., Smith, A. V., Glazer, N. L., Chen, M. H., Chasman, D. I., Aspelund, T., Eiriksdottir, G., Harris, T. B., Launer, L., Nalls, M., Hernandez, D., Arking, D. E., Boerwinkle, E., Grove, M. L., Li, M., Linda Kao, W. H., Chonchol, M., Haritunians, T., Li, G., Lumley, T., Psaty, B. M., Shlipak, M., Hwang, S. J., Larson, M. G., OöDonnell, C. J., Upadhyay, A., van Duijn, C. M., Hofman, A., Rivadeneira, F., Stricker, B., Uitterlinden, A. G., Paré, G., Parker, A. N., Ridker, P. M., Siscovick, D. S., Gudnason, V., Witteman, J. C., Fox, C. S. and Coresh, J.: Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ. Cardiovasc. Genet., 3: 523-530 2010.
73. Dehghan, A., Köttgen, A., Yang, Q., Hwang, S. J., Kao, W. L., Rivadeneira, F., Boerwinkle, E., Levy, D., Hofman, A., Astor, B. C., Benjamin, E. J., van Duijn, C. M., Witteman, J. C., Coresh, J. and Fox, C. S.: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet, 372: 1953-1961 2008.
74. Jafar, T., Prasad, N., Agarwal, V., Mahdi, A., Gupta, A., Sharma, R. K., Negi, M. and Agrawal, S.: MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant., 26: 3968-3974 2011.
75. Dong, L., Luo, R., Tong, Y., Cai, X., Mao, M. and Yu, D.: Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. Brain Res., 1391: 114-124 2011.
76. Hoenig, M. R., Walker, P. J., Gurnsey, C., Beadle, K. and Johnson, L.: The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J. Clin. Lipidol., 5: 91-96 2011.
77. Haerian, B. S., Lim, K. S., Tan, H. J., Mohamed, E. H., Tan, C. T., Raymond, A. A., Wong, C. P., Wong, S. W., Omar, H., Roslan, H. and Mohamed, Z.: Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord., 13: 65-75 2011.
78. Zwisler, S. T., Enggaard, T. P., Mikkelsen, S., Verstuyft, C., Becquemont, L., Sindrup, S. H. and Brosen, K.: Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. J. Clin. Pharmacol., 2011 [Epub ahead of print].
79. Narumiya, K., Metzger, R., Bollschweiler, E., Alakus, H., Brabender, J., Drebber, U., Hölscher, A. H. and Warnecke- Eberz, U.: Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics, 12: 205-214 2011.
80. Saricaoglu, H., Yilmaz, M., Karkucak, M., Ozturk, H. Z., Yakut, T., Gulten, T., Baskan, E. B., Aydogan, K. and Dilek, K.: Investigation of ABCB1 gene polymorphism with colchicine response in Behçet's disease. Genet. Mol. Res., 10: 1-6 2011.
81. Obermann-Borst, S. A., Isaacs, A., Younes, Z., van Schaik, R. H., van der Heiden, I. P., van Duyn, C. M., Steegers, E. A. and Steegers-Theunissen, R. P.: General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. Am. J. Obstet. Gynecol., 204: 236.e1-236.e8 2011.
82. Gonzalez-Haba, E., García, M. I., Cortejoso, L., López-Lillo, C., Barrueco, N., García-Alfonso, P., Alvarez, S., Jiménez, J. L., Martín, M. L., Muñóz-Fernández, M. A., Sanjurjo, M. and López-Fernández, L. A.: ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics, 11: 1715-1723 2010.
83. Rao, D. N., Anuradha, C., Vishnupriya, S., Sailaja, K., Surekha, D., Raghunadharao, D. and Rajappa, S.: Association of an MDR1 gene C3435T polymorphism with acute leukemia in India. Asian Pac. J. Cancer Prev., 11: 1063-1066 2010.
84. Parkman, H. P., Jacobs, M. R., Mishra, A., Hurdle, J. A., Sachdeva, P., Gaughan, J. P. and Krynetskiy, E.: Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig. Dis. Sci., 56: 115-124 2011.
85. Fransson, M. N., Gréen, H., Litton, J. E. and Friberg, L. E.: Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab. Dispos., 39: 247-255 2011.
86. Herrero, M. J., Almenar, L., Jordán, C., Sánchez, I., Poveda, J. L. and Aliño, S. F.: Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. Transplant. Proc., 42: 3181-3182 2010.
87. Grimm, C., Polterauer, S., Zeillinger, R., Tong, D., Heinze, G., Wolf, A., Natter, C., Reinthaller, A. and Hefler, L. A.: Two multidrug-resistance ABCB1 gene polymorphisms as prognostic parameters in women with ovarian cancer. Anticancer Res., 30: 3487-3491 2010.
88. Elens, L., Vandercam, B., Yombi, J. C., Lison, D., Wallemacq, P. and Haufroid, V.: Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics, 11: 1223-1234 2010.
89. Shitara, K., Matsuo, K., Ito, S., Sawaki, A., Kawai, H., Yokota, T., Takahari, D., Shibata, T., Ura, T., Ito, H., Hosono, S., Kawase, T., Watanabe, M., Tajima, K., Yatabe, Y., Tanaka, H. and Muro, K.: Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac. J. Cancer Prev., 11: 447-452 2010.
90. Wallentin, L., James, S., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J., Husted, S., Katus, H., Steg, P. G., Shah, S. H. and Becker, R. C.: PLATO investigators: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 376: 1320-1328 2010.
91. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Walker, J. R., Simon, T., Antman, E. M., Braunwald, E. and Sabatine, M. S.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet, 376: 1312-1319 2010.
92. Choi, E. M., Lee, M. G., Lee, S. H., Choi, K. W. and Choi, S. H.: Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia, 65: 996-1000 2010.
93. Menu, P., Gressier, F., Verstuyft, C., Hardy, P., Becquemont, L. and Corruble, E.: Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology, 62: 193-197 2010.
94. Fajac, A., Gligorov, J., Rezai, K., Lévy, P., Lévy, E., Selle, F., Beerblock, K., Avenin, D., Saintigny, P., Hugonin, S., Bernaudin, J. F. and Lokiec, F.: Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br. J. Cancer, 103: 560-566 2010.
95. Sia, A. T., Sng, B. L., Lim, E. C., Law, H. and Tan, E. C.: The influence of ATP-binding cassette sub-family B member-1 ABCB1 genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int. J. Obstet. Anesth., 19: 254-260 2010.
96. Lu, P. H., Wei, M. X., Yang, J., Liu, X., Tao, G. Q., Shen, W. and Chen, M. B.: Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a metaanalysis. Breast Cancer Res. Treat., 125: 537-543 2011.
97. Jovanović, N., Božina, N., Lovrić, M., Medved, V., Jakovljević, M. and Peleš, A. M.: The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol., 66: 1109-1117 2010.
98. Dutheil, F., Beaune, P., Tzourio, C., Loriot, M. A. and Elbaz, A.: Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch. Neurol., 67: 739-745 2010.
99. Sarginson, J. E., Lazzeroni, L. C., Ryan, H. S., Ershoff, B. D., Schatzberg, A. F. and Murphy, G. M., Jr.: ABCB1 MDR1 polymorphisms and antidepressant response in geriatric depression. Pharmacogenet. Genomics, 20: 467-475 2010.
100. Balcerczak, E., Panczyk, M., Piaskowski, S., Pasz-Walczak, G., Sałagacka, A. and Mirowski, M.: ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int. J. Colorectal Dis., 25: 1167-1176 2010.
101. Buda, G., Ricci, D., Huang, C. C., Favis, R., Cohen, N., Zhuang, S. H., Harousseau, J. L., Sonneveld, P., Bladé, J. and Orlowski, R. Z.: Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann. Hematol., 89: 1133-1140 2010.
102. Woillard, J. B., Rerolle, J. P., Picard, N., Rousseau, A., Guillaudeau, A., Munteanu, E., Essig, M., Drouet, M., Le Meur, Y. and Marquet, P.: Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin. Pharmacol. Ther., 88: 95-100 2010.
103. Park, W. B., Choe, P. G., Song, K. H., Jeon, J. H., Park, S. W., Kim, H. B., Kim, N. J., Oh, M. D. and Choe, K. W.: Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin. Infect. Dis., 51: 101-106 2010.
104. Cho, H. Y., Yoo, H. D. and Lee, Y. B.: Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience, 169: 378-387 2010.
105. Xiang, Q., Zhao, X., Zhou, Y., Duan, J. L. and Cui, Y. M.: Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J. Clin. Pharmacol., 50: 659-666 2010.
106. Ni, L. N., Li, J. Y., Miao, K. R., Qiao, C., Zhang, S. J., Qiu, H. R. and Qian, S. X.: Multidrug resistance gene MDR1 polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol., 28: 265-269 2011.
107. McCracken, J. T., Aman, M. G., McDougle, C. J., Tierney, E., Shiraga, S., Whelan, F., Arnold, L. E., Posey, D., Ritz, L., Vitiello, B. and Scahill, L.: Possible influence of variant of the P-glycoprotein gene MDR1/ABCB1 on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J. Child Adolesc. Psychopharmacol., 20: 1-5 2010.
108. Choi, B. S., Alberti, D. B., Schelman, W. R., Kolesar, J. M., Thomas, J. P., Marnocha, R., Eickhoff, J. C., Ivy, S. P., Wilding, G. and Holen, K. D.: The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother. Pharmacol., 66: 973-980 2010.
109. Bellusci, C. P., Rocco, C. A., Aulicino, P. C., Mecikovsky, D., Bologna, R., Sen, L. and Mangano, A.: MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS, 24: 833-840 2010.
110. Cho, H. Y., Yoon, H., Park, G. K. and Lee, Y. B.: Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, twoperiod, two-sequence crossover study in healthy Korean male volunteers. Clin. Ther., 31: 2712-2721 2009.
111. Sánchez, M. B., Herranz, J. L., Leno, C., Arteaga, R., Oterino, A., Valdizán, E. M., Nicolás, J. M., Adín, J. and Armijo, J. A.: Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure, 19: 93-101 2010.
112. Taegtmeyer, A. B., Breen, J. B., Smith, J., Burke, M., Leaver, N., Pantelidis, P., Lyster, H., Yacoub, M. H., Barton, P. J. and Banner, N. R.: ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation, 89: 75-82 2010.
113. Kastelic, M., Koprivsek, J., Plesnicar, B. K., Serretti, A., Mandelli, L., Locatelli, I., Grabnar, I. and Dolzan, V.: MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 34: 387-392 2010.
114. Ciccacci, C., Borgiani, P., Ceffa, S., Sirianni, E., Marazzi, M. C., Altan, A. M., Paturzo, G., Bramanti, P., Novelli, G. and Palombi, L.: Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics, 11: 23-31 2010.
115. Chang, H., Rha, S. Y., Jeung, H. C., Im, C. K., Noh, S. H., Kim, J. J. and Chung, H. C.: Association of the ABCB1 3435ChT polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep., 23: 271-278 2010.
116. Andersen, V., Ostergaard, M., Christensen, J., Overvad, K., Tjønneland, A. and Vogel, U.: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 MDR1 and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer, 9: 407 2009.
117. He, X. J., Zhao, L. M., Qiu, F., Sun, Y. X. and Li-Ling, J.: Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol. Rep., 61: 843-850 2009.
118. Becker, M. L., Visser, L. E., van Schaik, R. H., Hofman, A., Uitterlinden, A. G. and Stricker, B. H.: Common genetic variation in the ABCB1 gene is associated with the cholesterollowering effect of simvastatin in males. Pharmacogenomics, 10: 1743-1751 2009.
119. Paule, B., Castagne, V., Picard, V., Saffroy, R., Adam, R., Guettier, C., Farinotti, R. and Bonhomme-Faivre, L.: MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med. Oncol., 27: 1066-1072 2010.
120. Zwisler, S. T., Enggaard, T. P., Noehr-Jensen, L., Mikkelsen, S., Verstuyft, C., Becquemont, L., Sindrup, S. H. and Brosen, K.: The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam. Clin. Pharmacol., 24: 517-524 2010.
121. Droździk, M., Stefankiewicz, J., Kurzawa, R., Górnik, W., Baczkowski, T. and Kurzawski, M.: Association of the MDR1 ABCB1 gene 3435ChT polymorphism with male infertility. Pharmacol. Rep., 61: 690-696 2009.
122. Bliek, B. J., van Schaik, R. H., van der Heiden, I. P., Sayed- Tabatabaei, F. A., van Duijn, C. M., Steegers, E. A. and Steegers- Theunissen, R. P.: Eurocran Gene-Environment Interaction Group: Maternal medication use, carriership of the ABCB1 3435C h T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am. J. Med. Genet. A., 149A: 2088- 2092 2009.
123. Hawwa, A. F., McKiernan, P. J., Shields, M., Millership, J. S., Collier, P. S. and McElnay, J. C.: Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br. J. Clin. Pharmacol., 68: 413-421 2009.
124. Zhao, L. M., He, X. J., Qiu, F., Sun, Y. X. and Li-Ling, J.: Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br. J. Clin. Pharmacol., 68: 395-401 2009.
125. Bonhomme-Faivre, L., Picard, V., Saliba, F., Abbara, C., Fodil, M., Chaunoy, M. and Farinotti, R.: Effect of the ABCB1 3435ChT polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am. J. Health Syst. Pharm., 66: 1645-1651 2009.
126. Keskitalo, J. E., Kurkinen, K. J., Neuvonen, M., Backman, J. T., Neuvonen, P. J. and Niemi, M.: No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br. J. Clin. Pharmacol., 68: 207-213 2009.
127. van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K., Mathijssen, R. H., Boven, E., van der Straaten, T., Baak-Pablo, R. F., Wessels, J. A., Guchelaar, H. J. and Gelderblom, H.: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol., 27: 4406-4412 2009.
128. Consoli, G., Lastella, M., Ciapparelli, A., Catena DellöOsso, M., Ciofi, L., Guidotti, E., Danesi, R., DellöOsso, L., Del Tacca, M. and Di Paolo, A.: ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics, 10: 1267-1276 2009.
129. George, J., Dharanipragada, K., Krishnamachari, S., Chandrasekaran, A., Sam, S. S. and Sunder, E.: A singlenucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin. Breast Cancer, 9: 161-165 2009.
130. Benyamina, A., Bonhomme-Faivre, L., Picard, V., Sabbagh, A., Richard, D., Blecha, L., Rahioui, H., Karila, L., Lukasiewicz, M., Farinotti, R., Picard, V., Marill, C. and Reynaud, M.: Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog. Neuropsychopharmacol. Biol. Psychiatry, 33: 1270-1274 2009.
131. Yin, O. Q., Tomlinson, B. and Chow, M. S.: Effect of multidrug resistance gene-1 ABCB1 polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men. Clin. Ther., 31: 999-1006 2009.
132. Panczyk, M., Balcerczak, E., Piaskowski, S., Jamroziak, K., Pasz- Walczak, G. and Mirowski, M.: ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int. J. Colorectal Dis., 24: 895-905 2009.
133. Drain, S., Catherwood, M. A., Orr, N., Galligan, L., Rea, I. M., Hodkinson, C., Drake, M. B., Kettle, P. J., Morris, T. C. and Alexander, H. D.: ABCB1 MDR1 rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk. Lymphoma, 50: 566-570 2009.
134. Lara, P. N., Jr., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., Chansky, K. and Gandara, D. R.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive- stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol., 27: 2530-2535 2009.
135. Tahara, T., Shibata, T., Nakamura, M., Yamashita, H., Yoshioka, D., Okubo, M., Maruyama, N., Kamano, T., Kamiya, Y., Nakagawa, Y., Fujita, H., Nagasaka, M., Iwata, M., Takahama, K., Watanabe, M., Hirata, I. and Arisawa, T.: Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int. J. Mol. Med., 23: 521-527 2009.
136. Hosohata, K., Masuda, S., Yonezawa, A., Katsura, T., Oike, F., Ogura, Y., Takada, Y., Egawa, H., Uemoto, S. and Inui, K.: MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res., 26: 1590-1595 2009.
137. Kodaira, C., Sugimoto, M., Nishino, M., Yamade, M., Shirai, N., Uchida, S., Ikuma, M., Yamada, S., Watanabe, H., Hishida, A. and Furuta, T.: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur. J. Clin. Pharmacol., 65: 593-600 2009.
138. Estrela, R. C., Ribeiro, F. S., Barroso, P. F., Tuyama, M., Gregório, S. P., Dias-Neto, E., Struchiner, C. J. and Suarez- Kurtz, G.: ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics, 10: 311-318 2009.
139. Westerlund, M., Belin, A. C., Anvret, A., Håkansson, A., Nissbrandt, H., Lind, C., Sydow, O., Olson, L. and Galter, D.: Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat. Disord., 15: 422-424 2009.
140. Ashariati, A.: Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med. Indones., 40: 187-191 2008.
141. Krupoves, A., Seidman, E. G., Mack, D., Israel, D., Morgan, K., Lambrette, P., Costea, I., Deslandres, C., Grimard, G., Law, L., Levy, E. and Amre, D. K.: Associations between ABCB1/MDR1 gene polymorphisms and Crohn's disease: a gene-wide study in a pediatric population. Inflamm. Bowel Dis., 15: 900-908 2009.
142. Guo, X., Chen, X. P., Cheng, Z. N., Luo, X., Guo, R., Chen, L., Chen, J., Chen, B., Peng, J. and Li, Y. J.: No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin. Chem. Lab. Med., 47: 38-43 2009.
143. Curras, V., Hocht, C., Mangano, A., Niselman, V., Mariño Hernández, E., Cáceres Guido, P., Mecikovsky, D., Bellusci, C., Bologna, R., Sen, L., Rubio, M. C. and Bramuglia, G.F.: Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology, 83: 59-66 2009.
144. Weiss, J., Ten Hoevel, M. M., Burhenne, J., Walter-Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E. and Mikus, G.: CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol., 49: 196-204 2009.
145. Juyal, G., Midha, V., Amre, D., Sood, A., Seidman, E. and Thelma, B. K.: Associations between common variants in the MDR1 ABCB1 gene and ulcerative colitis among North Indians. Pharmacogenet. Genomics, 19: 77-85 2009.
146. Bandur, S., Petrasek, J., Hribova, P., Novotna, E., Brabcova, I. and Viklicky, O.: Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation, 86: 1206-1213 2008.
147. Wang, Y., Wang, C., Li, J., Wang, X., Zhu, G., Chen, X., Bi, H. and Huang, M.: Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur. J. Clin. Pharmacol., 65: 239-247 2009.
148. Chang, H., Rha, S. Y., Jeung, H. C., Im, C. K., Ahn, J. B., Kwon, W. S., Yoo, N. C., Roh, J. K. and Chung, H. C.: Association of the ABCB1 gene polymorphisms 2677GhT/A and 3435ChT with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol., 20: 272-277 2009.
149. Gonzalez, T. P., Mucenic, T., Brenol, J. C., Xavier, R. M., Schiengold, M. and Chies, J. A.: ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz. J. Med. Biol. Res., 41: 769-772 2008.
150. Yasar, U., Babaoglu, M. O. and Bozkurt, A.: Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C h T variation of the drug transporter gene ABCB1 MDR1. Basic Clin. Pharmacol. Toxicol., 103: 176-179 2008.
151. Xu, P., Jiang, Z. P., Zhang, B. K., Tu, J. Y. and Li, H. D.: Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology, 82: 221-227 2008.
152. Kuzman, M. R., Medved, V., Bozina, N., Hotujac, L., Sain, I. and Bilusic, H.: The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res., 160: 308-315 2008.
153. Gunes, A., Spina, E., Dahl, M. L. and Scordo, M. G.: ABCB1 polymorphisms influence steady-state plasma levels of 9-hydrox-yrisperidone and risperidone active moiety. Ther. Drug Monit., 30: 628-633 2008.
154. De Iudicibus, S., Castronovo, G., Gigante, A., Stocco, G., Decorti, G., Di Lenarda, R. and Bartoli, F.: Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. J. Periodontal Res., 43: 665-672 2008.
155. Schaich, M., Kestel, L., Pfirrmann, M., Robel, K., Illmer, T., Kramer, M., Dill, C., Ehninger, G., Schackert, G. and Krex, D.: A MDR1 ABCB1 gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol., 20: 175-181 2009.
156. Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Yamade, M., Ikuma, M., Sugimura, H., Ishizaki, T. and Hishida, A.: MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci., 83: 301-304 2008.
157. Jamroziak, K., Balcerczak, E., Calka, K., Piaskowski, S., Urbanska-Rys, H., Salagacka, A., Mirowski, M. and Robak, T.: Polymorphisms and haplotypes in the multidrug resistance 1 gene MDR1/ABCB1 and risk of multiple myeloma. Leuk. Res., 33: 332-335 2009.
158. Sissung, T. M., Baum, C. E., Deeken, J., Price, D. K., Aragon- Ching, J., Steinberg, S. M., Dahut, W., Sparreboom, A. and Figg, W. D.: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res., 14: 4543-4549 2008.
159. Beringer, P. M., Kriengkauykiat, J., Zhang, X., Hidayat, L., Liu, S., Louie, S., Synold, T., Burckart, G. J., Rao, P. A., Shapiro, B. and Gill, M.: Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy, 28: 883-894 2008.
160. Mihaljevic Peles, A., Bozina, N., Sagud, M., Rojnic Kuzman, M. and Lovric, M.: MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32: 1439-1444 2008.
161. Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M. and Mahon, F. X.: Multidrug resistance gene MDR1 polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 112: 2024-2027 2008.
162. Hesselink, D. A., van Schaik, R. H., Nauta, J. and van Gelder, T.: A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics, 9: 783-789 2008.
163. Zhang, Y, Jiang, X. H., Hu, Y. Q., Li, Z. R., Su, L., Wang, Z. G. and Ma, G.: MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br. J. Clin. Pharmacol., 66: 247-254 2008.
164. Ichihara, S., Yamada, Y., Kato, K., Hibino, T., Yokoi, K., Matsuo, H., Kojima, T., Watanabe, S., Metoki, N., Yoshida, H., Satoh, K., Aoyagi, Y., Yasunaga, A., Park, H., Tanaka, M. and Nozawa, Y.: Association of a polymorphism of ABCB1 with obesity in Japanese individuals. Genomics, 91: 512-516 2008.
165. Levran, O., OöHara, K., Peles, E., Li, D., Barral, S., Ray, B., Borg, L., Ott, J., Adelson, M. and Kreek, M. J.: ABCB1 MDR1 genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet., 17: 2219-2227 2008.
166. Maggini, V., Buda, G., Martino, A., Presciuttini, S., Galimberti, S., Orciuolo, E., Barale, R., Petrini, M. and Rossi, A. M.: MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet. Genomics, 18: 383-389 2008.
167. Maruyama, K., Harada, S., Yokoyama, A., Naruse, S., Hirota, M., Nishimori, I. and Otsuki, M.: Association analysis among polymorphisms of the various genes and chronic alcoholic pancreatitis. J. Gastroenterol. Hepatol., 23: S69-S72 2008.
168. Lal, S., Wong, Z. W., Sandanaraj, E., Xiang, X., Ang, P. C., Lee, E. J. and Chowbay, B.: Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci., 99: 816-823 2008.
169. Pan, W., Ryu, J. Y., Shon, J. H., Song, I. S., Liu, K. H., Sunwoo, Y. E., Kang, W. and Shin, J. G.: Dietary salt does not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects. Xenobiotica, 38: 422-434 2008.
170. Aarnoudse, A. J., Dieleman, J. P., Visser, L. E., Arp, P. P., van der Heiden, I. P., van Schaik, R. H., Molokhia, M., Hofman, A., Uitterlinden, A. G. and Stricker, B. H.: Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet. Genomics, 18: 299-305 2008.
171. Basic, S., Hajnsek, S., Bozina, N., Filipcic, I., Sporis, D., Mislov, D. and Posavec, A.: The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the bloodbrain barrier in patients with generalized epilepsy. Seizure, 17: 524-530 2008.
172. Ross, J. R., Riley, J., Taegetmeyer, A. B., Sato, H., Gretton, S., du Bois, R. M. and Welsh, K. I.: Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer, 112: 1390-1403 2008.
173. Yang, X. Y. and Xu, D. H.: MDR1 ABCB1 gene polymorphisms associated with steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie, 62: 930-932 2007.
174. Turgut, G., Kurt, E., Sengul, C., Alatas, G., Kursunluoglu, R., Oral, T., Turgut, S. and Herken, H.: Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol. Biol. Rep., 36: 495-499 2009.
175. Ozgon, G. O., Bebek, N., Gul, G. and Cine, N.: Association of MDR1 C3435T polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur. Neurol., 59: 67-70 2008.
176. Mihaljević-Peles, A., Bozina, N. and Sagud, M.: Pharmacogenetics in modern psychiatry. Psychiatr. Danub., 19: 231-233 2007.
177. Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M., Kohli, M., Kloiber, S., Salyakina, D., Bettecken, T., Specht, M., Pütz, B., Binder, E. B., Müller-Myhsok, B. and Holsboer, F.: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57: 203-209 2008.
178. Kato, M., Fukuda, T., Serretti, A., Wakeno, M., Okugawa, G., Ikenaga, Y., Hosoi, Y., Takekita, Y., Mandelli, L., Azuma, J. and Kinoshita, T.: ABCB1 MDR1 gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32: 398-404 2008.
179. Campa, D., Gioia, A., Tomei, A., Poli, P. and Barale, R.: Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther., 83: 559-566 2008.
180. Turgut, G., Baştemir, M., Turgut, S., Akin, F., Kursunluoglu, R. and Kaptanoǧlu, B.: P-glycoprotein polymorphism in hypo- and hyper-thyroidism patients. Mol. Biol. Rep., 35: 693-698 2008.
181. Sam, S. S., Thomas, V., Sivagnanam, K., Reddy, K. S., Surianarayanan, G. and Chandrasekaran, A.: ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenet. Genomics, 17: 861-866 2007.
182. Pan, J. H., Han, J. X., Wu, J. M., Sheng, L. J., Huang, H. N. and Yu, Q. Z.: MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with nonsmall cell lung cancer. Respiration, 75: 380-385 2008.
183. Gréen, H., Söderkvist, P., Rosenberg, P., Horvath, G. and Peterson, C.: ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci., 97: 2045-2048 2008.
184. Furuta, T., Sugimoto, M., Shirai, N., Matsushita, F., Nakajima, H., Kumagai, J., Senoo, K., Kodaira, C., Nishino, M., Yamade, M., Ikuma, M., Watanabe, H., Umemura, K., Ishizaki, T. and Hishida, A.: Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther., 26: 693-703 2007.
185. Fiedler, T., Büning, C., Reuter, W., Pitre, G., Gentz, E., Schmidt, H. H., Büttner, J., Ockenga, J., Gerloff, T., Meisel, C., Lochs, H., Roots, I., Köpke, K. and Johne, A.: Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur. J. Clin. Pharmacol., 63: 917-925 2007.
186. Tufan, A., Babaoglu, M. O., Akdogan, A., Yasar, U., Calguneri, M., Kalyoncu, U., Karadag, O., Hayran, M., Ertenli, A. I., Bozkurt, A. and Kiraz, S.: Association of drug transporter gene ABCB1 MDR1 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J. Rheumatol., 34: 1540-1544 2007.
187. Hattori, H., Suminoe, A., Wada, M., Koga, Y., Kohno, K., Okamura, J., Hara, T. and Matsuzaki, A.: Regulatory polymorphisms of multidrug resistance 1 MDR1 gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk. Res., 31: 1633-1640 2007.
188. Turgut, S., Yaren, A., Kursunluoglu, R. and Turgut, G.: MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res., 38: 539-544 2007.
189. Yasui-Furukori, N., Tsuchimine, S., Saito, M., Nakagami, T., Sato, Y. and Kaneko, S.: Association between major Multidrug Resistance 1 MDR1 gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31: 1230-1234 2007.
190. Urayama, K. Y., Wiencke, J. K., Buffler, P. A., Chokkalingam, A. P., Metayer, C. and Wiemels, J. L.: MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol. Biomarkers Prev., 16: 1172-1177 2007.
191. Gurney, H., Wong, M., Balleine, R. L., Rivory, L. P., McLachlan, A. J., Hoskins, J. M., Wilcken, N., Clarke, C. L., Mann, G. J., Collins, M., Delforce, S. E., Lynch, K. and Schran, H.: Imatinib disposition and ABCB1 MDR1, P-glycoprotein genotype. Clin. Pharmacol. Ther., 82: 33-40 2007.
192. Buda, G., Maggini, V., Galimberti, S., Martino, A., Giuliani, N., Morabito, F., Genestreti, G., Iacopino, P., Rizzoli, V., Barale, R., Rossi, A. M. and Petrini, M.: MDR1 polymorphism influences the outcome of multiple myeloma patients. Br. J. Haematol., 137: 454-456 2007.
193. Wu, L., Xu, X., Shen, J., Xie, H., Yu, S., Liang, T., Wang, W., Shen, Y., Zhang, M. and Zheng, S.: MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J. Surg. Oncol., 96: 62-68 2007.
194. Kang, H. A., Cho, H. Y. and Lee, Y. B.: The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Arch. Pharm. Res., 30: 96-101 2007.
195. Ma, Q., Brazeau, D., Zingman, B. S., Reichman, R. C., Fischl, M. A., Gripshover, B. M., Venuto, C. S., Slish, J. C., DiFrancesco, R., Forrest, A. and Morse, G. D.: Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics, 8: 227-235 2007.
196. Mrozikiewicz, P. M., Seremak-Mrozikiewicz, A., Semczuk, A., Landt, O., Breborowicz, G. H. and Drews, K.: The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int. J. Gynecol. Cancer, 17: 728-731 2007.
197. Mendoza, J. L., Urcelay, E., Lana, R., Martín, M. C., López, N., Guijarro, L. G., Mayol, J. A., Taxonera, C., de la Concha, E. G., Peña, A. S. and Díaz-Rubio, M.: MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm. Bowel Dis., 13: 585-590 2007.
198. Ardizzone, S., Maconi, G., Bianchi, V., Russo, A., Colombo, E., Cassinotti, A., Penati, C., Tenchini, M. L. and Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis., 13: 516-523 2007.
199. Park, H. J., Shinn, H. K., Ryu, S. H., Lee, H. S., Park, C. S. and Kang, J. H.: Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin. Pharmacol. Ther., 81: 539-546 2007.
200. Miura, M., Satoh, S., Tada, H., Saito, M., Kagaya, H., Inoue, K., Sagae, Y., Kanno, S., Ishikawa, M., Habuchi, T. and Suzuki, T.: Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int. J. Clin. Pharmacol. Ther., 44: 605-613 2006.
201. Takatori, R., Takahashi, K. A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T., Hirata, T., Kawahito, Y., Satomi, Y., Nishino, H., Tanaka, T., Hirota, Y. and Kubo, T.: ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 24: 546-554 2006.
202. Coller, J. K., Barratt, D. T., Dahlen, K., Loennechen, M. H. and Somogyi, A. A.: ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther., 80: 682-690 2006.
203. Rodríguez-Nóvoa, S., Martín-Carbonero, L., Barreiro, P., González-Pardo, G., Jiménez-Nácher, I., González-Lahoz, J. and Soriano, V.: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS, 21: 41-46 2007.
204. Gervasini, G., Carrillo, J. A., Garcia, M., San Jose, C., Cabanillas, A. and Benitez, J.: Adenosine triphosphate-binding cassette B1 ABCB1 multidrug resistance 1 G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer, 107: 2850-2857 2006.
205. Bozina, N., Kuzman, M. R., Medved, V., Jovanovic, N., Sertic, J. and Hotujac, L.: Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatr. Res., 42: 89-97 2008.
206. Taubert, D., von Beckerath, N., Grimberg, G., Lazar, A., Jung, N., Goeser, T., Kastrati, A., Schömig, A. and Schömig, E.: Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther., 80: 486-501 2006.
207. Jamroziak, K., Balcerczak, E., Smolewski, P., Robey, R. W., Cebula, B., Panczyk, M., Kowalczyk, M., Szmigielska-Kapłon, A., Mirowski, M., Bates, S. E. and Robak, T.: MDR1 ABCB1 gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol. Rep., 58: 720-728 2006.
208. Xing, Q., Gao, R., Li, H., Feng, G., Xu, M., Duan, S., Meng, J., Zhang, A., Qin, S. and He, L.: Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7: 987-993 2006.
209. Lin, Y. C., Ellingrod, V. L., Bishop, J. R. and Miller, D. D.: The relationship between P-glycoprotein PGP polymorphisms and response to olanzapine treatment in schizophrenia. Ther. Drug Monit., 28: 668-672 2006.
210. Aarnoudse, A. L., van Schaik, R. H., Dieleman, J., Molokhia, M., van Riemsdijk, M. M., Ligthelm, R. J., Overbosch, D., van der Heiden, I. P. and Stricker, B. H.: MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther., 80: 367-374 2006.
211. Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D., Sparreboom, A. and Mielke, S.: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer, 42: 2893-2896 2006.
212. Drozdzik, M., Rudas, T., Pawlik, A., Kurzawski, M., Czerny, B., Gornik, W. and Herczynska, M.: The effect of 3435ChT MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol., 62: 933-937 2006.
213. Haas, D. W., Bartlett, J. A., Andersen, J. W., Sanne, I., Wilkinson, G. R., Hinkle, J., Rousseau, F., Ingram, C. D., Shaw, A., Lederman, M. M. and Kim, R. B.: Adult AIDS Clinical Trials Group: Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis., 43: 783-786 2006.
214. Kim, K. A., Park, P. W. and Park, J. Y.: Effect of ABCB1 MDR1 haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br. J. Clin. Pharmacol., 63: 53-58 2007.
215. Leschziner, G., Jorgensen, A. L., Andrew, T., Pirmohamed, M., Williamson, P. R., Marson, A. G., Coffey, A. J., Middleditch, C., Rogers, J., Bentley, D. R., Chadwick, D. W., Balding, D. J. and Johnson, M. R.: Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol., 5: 668-676 2006.
216. Kim, D. H., Park, J. Y., Sohn, S. K., Lee, N. Y., Suh, J. S. and Lee, K. B.: The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation. Haematologica, 91: 848-851 2006.
217. Dilger, K., Cascorbi, I., Grünhage, F., Hohenester, S., Sauerbruch, T. and Beuers, U.: Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int., 26: 285-290 2006.
218. Cho, H. Y., Park, S. A. and Lee, Y. B.: Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 834: 84-92 2006.
219. Sohn, J. W., Lee, S. Y., Lee, S. J., Kim, E. J., Cha, S. I., Kim, C. H., Lee, J. T., Jung, T. H. and Park, J. Y.: MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn. J. Clin. Oncol., 36: 137-141 2006.
220. Gréen, H., Söderkvist, P., Rosenberg, P., Horvath, G. and Peterson, C.: mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res., 12: 854-859 2006.
221. Meisel, P., Giebel, J., Kunert-Keil, C., Dazert, P., Kroemer, H. K. and Kocher, T.: MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clin. Pharmacol. Ther., 79: 62-71 2006.
222. Rodríguez Nóvoa, S., Barreiro, P., Rendón, A., Barrios, A., Corral, A., Jiménez-Nacher, I., González-Lahoz, J. and Soriano, V.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435CGT polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis., 42: 291-295 2006.
223. Kim, K. A., Joo, H. J. and Park, J. Y.: Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur. J. Clin. Pharmacol., 67: 129-134 2011.
224. Phipps-Green, A. J., Hollis-Moffatt, J. E., Dalbeth, N., Merriman, M. E., Topless, R., Gow, P. J., Harrison, A. A., Highton, J., Jones, P. B., Stamp, L. K. and Merriman, T. R.: A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. Hum. Mol. Genet., 19: 4813-4819 2010.
225. Takahashi, N., Miura, M., Scott, S. A., Kagaya, H., Kameoka, Y., Tagawa, H., Saitoh, H., Fujishima, N., Yoshioka, T., Hirokawa, M. and Sawada, K.: Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet., 55: 731-737 2010.
226. Tabara, Y., Kohara, K., Kawamoto, R., Hiura, Y., Nishimura, K., Morisaki, T., Kokubo, Y., Okamura, T., Tomoike, H., Iwai, N. and Miki, T.: Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study. Am. J. Nephrol., 32: 279-286 2010.
227. Yamagishi, K., Tanigawa, T., Kitamura, A., Köttgen, A., Folsom, A. R. and Iso, H.: CIRCS Investigators: The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. Rheumatology Oxford, 49: 1461-1465 2010.
228. Stamp, L. K., Chapman, P. T., OöDonnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A. and Roberts, R. L.: Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet. Genomics, 20: 367-376 2010.
229. Bailey, K. M., Romaine, S. P., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., Copeland, J., McCormack, T., Whitehead, A., Flather, M. D., Samani, N. J., Nixon, J., Hall, A. S. and Balmforth, A. J.: SPACE ROCKET Trial Group: Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ. Cardiovasc. Genet., 3: 276-285 2010.
230. Steeghs, N., Mathijssen, R. H., Wessels, J. A., de Graan, A. J., van der Straaten, T., Mariani, M., Laffranchi, B., Comis, S., de Jonge, M. J., Gelderblom, H. and Guchelaar, H. J.: Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest. New Drugs, 29: 953-962 2011.
231. Tomlinson, B., Hu, M., Lee, V. W., Lui, S. S., Chu, T. T., Poon, E. W., Ko, G. T., Baum, L., Tam, L. S. and Li, E. K.: ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther., 87: 558-562 2010.
232. Brandstätter, A., Lamina, C., Kiechl, S., Hunt, S. C., Coassin, S., Paulweber, B., Kramer, F., Summerer, M., Willeit, J., Kedenko, L., Adams, T. D. and Kronenberg, F.: Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis, 210: 474-478 2010.
233. Steeghs, N., Gelderblom, H., Wessels, J., Eskens, F. A., de Bont, N., Nortier, J. W. and Guchelaar, H. J.: Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest. New Drugs, 29: 137-143 2011.
234. Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J. and Niemi, M.: Different effects of the ABCG2 c.421ChA SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics, 10: 1617-1624 2009.
235. Cha, P. C., Mushiroda, T., Zembutsu, H., Harada, H., Shinoda, N., Kawamoto, S., Shimoyama, R., Nishidate, T., Furuhata, T., Sasaki, K., Hirata, K. and Nakamura, Y.: Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J. Hum. Genet., 54: 572-580 2009.
236. Cotte, S., von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U. K., Starck, M., König, N., Tellez, N., Dörr, J., Paul, F., Zipp, F., Lühder, F., Koepsell, H., Pannek, H., Montalban, X., Gold, R. and Chan, A.: ABC-transporter genepolymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain, 132: 2517-2530 2009.
237. Kim, D. H., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H. A. and Lipton, J. H.: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res., 15: 4750-4758 2009.
238. Adkison, K. K., Vaidya, S. S., Lee, D. Y., Koo, S. H., Li, L., Mehta, A. A., Gross, A. S., Polli, J. W., Humphreys, J. E., Lou, Y. and Lee, E. J.: Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation C421A and pantoprazole coadministration. J. Pharm. Sci., 99: 1046-1062 2010.
239. Woodward, O. M., Köttgen, A., Coresh, J., Boerwinkle, E., Guggino, W. B. and Köttgen, M.: Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. USA, 106: 10338-10342 2009.
240. Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J. and Niemi, M.: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther., 86: 197-203 2009.
241. Kim, I. S., Kim, H. G., Kim, D. C., Eom, H. S., Kong, S. Y., Shin, H. J., Hwang, S. H., Lee, E. Y. and Lee, G. W.: ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone chemotherapy. Cancer Sci., 99: 2496-2501 2008.
242. Luke, M. M., OöMeara, E. S., Rowland, C. M., Shiffman, D., Bare, L. A., Arellano, A. R., Longstreth, W. T., Jr., Lumley, T., Rice, K., Tracy, R. P., Devlin, J. J. and Psaty, B. M.: Gene variants associated with ischemic stroke: the cardiovascular health study. Stroke, 40: 363-368 2009.
243. Petain, A., Kattygnarath, D., Azard, J., Chatelut, E., Delbaldo, C., Geoerger, B., Barrois, M., Séronie-Vivien, S., LeCesne, A. and Vassal, G.: Innovative Therapies with Children with Cancer European consortium: Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res., 14: 7102-7109 2008.
244. Campa, D., Pardini, B., Naccarati, A., Vodickova, L., Novotny, J., Försti, A., Hemminki, K., Barale, R., Vodicka, P. and Canzian, F.: A gene-wide investigation on polymorphisms in the ABCG2/BRCP transporter and susceptibility to colorectal cancer. Mutat. Res., 645: 56-60 2008.
245. Adkison, K. K., Vaidya, S. S., Lee, D. Y., Koo, S. H., Li, L., Mehta, A. A., Gross, A. S., Polli, J. W., Lou, Y. and Lee, E. J.: The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br. J. Clin. Pharmacol., 66: 233-239 2008.
246. Urquhart, B. L., Ware, J. A., Tirona, R. G., Ho, R. H., Leake, B. F., Schwarz, U. I., Zaher, H., Palandra, J., Gregor, J. C., Dresser, G. K. and Kim, R. B.: Breast cancer resistance protein ABCG2 and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics, 18: 439-448 2008.
247. Kim, H. S., Sunwoo, Y. E., Ryu, J. Y., Kang, H. J., Jung, H. E., Song, I. S., Kim, E. Y., Shim, J. C., Shon, J. H. and Shin, J. G.: The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br. J. Clin. Pharmacol., 64: 645-654 2007.
248. Hu, L. L., Wang, X. X., Chen, X., Chang, J., Li, C., Zhang, Y., Yang, J., Jiang, W. and Zhuang, S. M.: BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis, 28: 1740-1744 2007.
249. Hahn, N. M., Marsh, S., Fisher, W., Langdon, R., Zon, R., Browning, M., Johnson, C. S., Scott-Horton, T. J., Li, L., McLeod, H. L. and Sweeney, C. J.: Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin. Cancer Res., 12: 6094-6099 2006.
250. Korenaga, Y., Naito, K., Okayama, N., Hirata, H., Suehiro, Y., Hamanaka, Y., Matsuyama, H. and Hinoda, Y.: Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int. J. Cancer, 117: 431-434 2005.